CervoMed (CRVO) Current Deferred Revenue (2023 - 2024)

CervoMed (CRVO) posted Current Deferred Revenue of $1.4 million for Q2 2024, up 144.81% sequentially from $572475.0 in Q1 2024.

CervoMed (CRVO) Current Deferred Revenue (2023 - 2024) Analysis & Trends

CervoMed has reported Current Deferred Revenue for 2 years, with the latest figure at $1.4 million in Q2 2024.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Vertex Pharmaceuticals	139.13 Bn	131.28 Bn	2.84 Bn
2	Regeneron Pharmaceuticals	85.77 Bn	77.77 Bn	3.93 Bn
3	Argenx Se	64.64 Bn	59.46 Bn	1.37 Bn
4	Moderna	58.29 Bn	53.16 Bn	52.00 Mn
5	BeOne Medicines	41.92 Bn	36.82 Bn	1.53 Bn
6	Alnylam Pharmaceuticals	31.58 Bn	28.28 Bn	992.69 Mn
7	BioNTech SE	28.12 Bn	9.73 Bn	668.28 Mn
8	Insmed	27.39 Bn	26.22 Bn	358.27 Mn
9	Royalty Pharma	27.27 Bn	26.43 Bn	-
10	CervoMed	26.64 Mn	26.64 Mn	-

Download Data